Product Overview
Unlike full-length thymosin beta‑4, FRAG 17–23 contains only the seven-amino-acid sequence associated with its actin-binding region. Researchers use this fragment to investigate peptide–actin interactions, cell motility, structure–activity relationships, and related cellular signaling pathways.
All reported findings are experimental and do not establish safety or effectiveness in humans.
Product Details
- Product: FRAG 17–23
- Common name: TB‑500 Fragment
- Parent peptide: Thymosin beta‑4
- Sequence: Ac‑LKKTETQ‑OH
- Peptide length: 7 amino acids
- Molecular formula: C₃₈H₆₈N₁₀O₁₄
- Molecular weight: 889.01 g/mol
- CAS number: 885340‑08‑9
- Amount: 10 mg per vial
- Form: Lyophilized research material
- Purity and testing: Refer to the batch-specific Certificate of Analysis
Research Applications
FRAG 17–23 may be studied in controlled laboratory settings involving:
- Actin-binding and cytoskeletal research
- Cellular migration and motility models
- Endothelial-cell response studies
- Experimental tissue-repair signaling
- Peptide structure–activity analysis
Storage and Handling
Store sealed at −20°C or colder, protected from moisture and light. Follow the storage requirements listed on the batch-specific Certificate of Analysis. Handle only with appropriate laboratory procedures and personal protective equipment.
Research-Use Notice
FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.
This product is not a drug, food, dietary supplement, or cosmetic. It is not intended to diagnose, treat, cure, or prevent any disease. No directions for human administration or dosage are provided. Purchase and handling are restricted to qualified researchers who accept responsibility for compliance with applicable laws and regulations.




